PubRank

D L Azarnoff

Author PubWeight™ 77.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980 2.85
2 Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther 1969 2.75
3 Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol 1966 2.29
4 Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry 1999 2.03
5 Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med 1968 1.98
6 Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol 1969 1.86
7 Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973 1.55
8 The effect of spironolactone on antipyrine metabolism in man. Pharmacology 1973 1.31
9 Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993 1.30
10 Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol 1974 1.28
11 Absorption of orally given digoxin preparations. JAMA 1972 1.27
12 The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet 1977 1.25
13 Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974 1.22
14 Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol 1974 1.21
15 Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci 1976 1.14
16 Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther 1976 1.14
17 Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation 1969 1.11
18 Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci 1978 1.09
19 Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res 1979 1.09
20 Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci 1977 1.07
21 Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am 1973 1.06
22 Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 1972 1.04
23 Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology 1974 1.02
24 Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res 1979 1.00
25 The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology 1972 1.00
26 Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther 1978 0.99
27 Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978 0.99
28 Prescription writing by generic name and drug cost. J Chronic Dis 1967 0.96
29 Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther 1977 0.95
30 A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol 1970 0.95
31 Drug interactions with warfarin. Arch Intern Med 1968 0.95
32 Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther 1975 0.94
33 Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther 1969 0.93
34 Drug interactions. Pharmacol Physicians 1970 0.93
35 Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet 1976 0.92
36 Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res 1974 0.92
37 Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 1975 0.92
38 The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther 1966 0.87
39 Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet 1983 0.87
40 Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism 1968 0.86
41 Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther 1972 0.86
42 Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology 1975 0.85
43 Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther 1978 0.85
44 Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J 1976 0.85
45 Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther 1974 0.85
46 Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis 1977 0.84
47 Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos 1981 0.84
48 Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther 1975 0.83
49 Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc 1971 0.83
50 Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci 1974 0.83
51 1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol 1975 0.82
52 Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res 1977 0.82
53 Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr 1975 0.81
54 Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther 1979 0.81
55 Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr 1978 0.81
56 Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol 1980 0.81
57 Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther 1978 0.81
58 Pharmacology of hypolipidemic drugs. Introduction. Fed Proc 1971 0.81
59 Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet 1990 0.80
60 Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol 1971 0.80
61 A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci 1977 0.80
62 The interaction between halofenate and propranolol. Clin Pharmacol Ther 1976 0.80
63 Serum digitoxin in uremic patients. Clin Pharmacol Ther 1972 0.79
64 Species differences in the plasma protein binding of desipramine. J Pharm Pharmacol 1968 0.79
65 The effect of DDD on barbiturate and steroid-induced hypnosis in the dog and rat. Biochem Pharmacol 1966 0.79
66 Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther 1978 0.79
67 Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt. J Pharm Sci 1974 0.78
68 The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin. Ann N Y Acad Sci 1973 0.78
69 Placental transfer and fetal urinary excretion of gentamicin during constant rate maternal infusion. Pediatr Res 1975 0.78
70 Hepatic catalase is not essential for the hypolipidemic action of peroxisome proliferators. Proc Soc Exp Biol Med 1977 0.78
71 Inhibition of amphetamine tolerance and metabolism by propranolol. J Pharmacol Exp Ther 1974 0.77
72 One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther 1976 0.76
73 Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm 1982 0.76
74 Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic. Am Rev Respir Dis 1973 0.76
75 Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. J Pharmacokinet Biopharm 1980 0.75
76 Current status of drugs used to treat hyperlipoproteinemias. Drug Ther 1982 0.75
77 Quantitation of chlordiazepoxide and its metabolites in biological fluids by thin-layer chromatography. J Chromatogr 1978 0.75
78 Physiologic factors in selecting human volunteers for drug studies. Clin Pharmacol Ther 1972 0.75
79 Half-life of methotrexate: new evidence. Arch Dermatol 1972 0.75
80 Placental transfer of penicillin G during constant-rate infusion in the goat. Am J Obstet Gynecol 1973 0.75
81 Proceedings: Pharmacokinetics of drugs in patients with nephrotic syndrome. Arzneimittelforschung 1976 0.75
82 In defense of the Drug Research Board. JAMA 1975 0.75
83 Intersubject variation in absorption of digoxin in normal volunteers. J Pharm Sci 1975 0.75
84 Quantitation of N-demethylantipyrine in biological samples and isolation and characterization of its glucuronic acid conjugate. Drug Metab Dispos 1978 0.75
85 Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1974 0.75
86 Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents. Biochem Pharmacol 1984 0.75
87 Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. Clin Pharmacol Ther 1998 0.75
88 Therapeutic implications of bioavailability. Annu Rev Pharmacol Toxicol 1976 0.75
89 In vitro inhibition of rat liver cholest-5en-3 beta-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagents. Steroids 1976 0.75
90 Use of pharmacokinetic principles in therapy. N Engl J Med 1973 0.75
91 Effect of drugs which alter microsomal drug-metabolizing enzyme activity on rat hepatic cholesterol biosynthesis. Biochem Pharmacol 1977 0.75
92 Effective drug use. Drug utilization by the practicing physician. J Kans Med Soc 1972 0.75
93 Clinical principles of drug interactions in the adult patient. Ann N Y Acad Sci 1976 0.75
94 Bioavailability of digoxin-hydroquinone complex: a new oral digoxin formulation. J Pharm Sci 1977 0.75
95 Separation and identification of impurities in parenteral methotrexate dosage forms. Cancer Treat Rep 1978 0.75
96 The use of digitalis. Ration Drug Ther 1974 0.75
97 Tumors potentiating catecholamine-induced hypertension. Life Sci I 1971 0.75
98 Application of blood level data to clinical trials. Clin Pharmacol Ther 1974 0.75
99 The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men. Circulation 1980 0.75
100 Proceedings: Alterations in the pharmacokinetics of drugs by portocaval shunt. Naunyn Schmiedebergs Arch Pharmacol 1975 0.75
101 The effect of spironolactone on plasma levels and excretion of testosterone and oestrogens in the urine in males. (A preliminary report). J Int Med Res 1974 0.75
102 A new method for increasing the chemotherapeutic drug concentration in the tumor tissue. Panminerva Med 1976 0.75
103 Evidence that inhibition of hepatic drug oxidation by tumors is mediated by a circulating humor. Proc Soc Exp Biol Med 1972 0.75
104 The profession of medicine. Pharmacology 1972 0.75
105 Drug interactions: clinical significance. Clin Pharmacol Ther 1974 0.75
106 Clinical implications of drug metabolism--introduction. Chem Biol Interact 1971 0.75
107 Methapyrilene kinetics and dynamics. Clin Pharmacol Ther 1981 0.75
108 High-pressure liquid chromatographic assay of theophylline in biological fluids. J Chromatogr 1974 0.75
109 Glutethimide and 4-OH glutethimide: pharmacokinetics and effect on performance in man. Clin Pharmacol Ther 1977 0.75
110 Drug inhibition of catecholamine-induced metabolic effects in humans. Ann N Y Acad Sci 1967 0.75
111 Identification of methotrexate and folic acid analogs by mass spectrometry. Biomed Mass Spectrom 1978 0.75
112 Effect of oxygen tension on drug levels and pharmacological action in the intact animal. Proc Soc Exp Biol Med 1969 0.75
113 Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. Clin Pharmacol Ther 1973 0.75
114 The effect of hypocholesterolemic drugs on adrenal corticosteroid secretion. Steroids 1967 0.75
115 Colestipol and clofibrate in hypercholesterolemia. Clin Pharmacol Ther 1974 0.75
116 Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug. Clin Pharmacol Ther 1978 0.75
117 The value of plasma-digoxin assay. Lancet 1972 0.75
118 Glucuronic acid conjugates of clofibrate: four isomeric structures. Life Sci 1981 0.75
119 Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine. Am J Med Sci 1971 0.75
120 Panel 3: phase III investigations. Clin Pharmacol Ther 1975 0.75
121 Drug development: risks and problems. Ann N Y Acad Sci 1984 0.75
122 The clinical use of plasma drug concentrations. Ration Drug Ther 1976 0.75
123 Individualization of treatment of hyperlipoproteinemic disorders. Med Clin North Am 1974 0.75
124 Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker. Clin Pharmacol Ther 1979 0.75
125 Separation and quantitative analysis of furosemide and 4-chloro-5-sulfamoylanthranilic adid (CSA) by high pressure liquid chromatography. Res Commun Chem Pathol Pharmacol 1975 0.75
126 Nitroglycerin patches: further comments. Am Pharm 1982 0.75
127 Insecticides: effect on drug metabolism. Clin Pharmacol Ther 1977 0.75
128 Effect of warfarin in treatment of cancer. Panminerva Med 1976 0.75
129 Placental transfer of diphenylhydantoin in the goat. Biochem Pharmacol 1972 0.75
130 Application of metabolic data to the evaluation of drugs. JAMA 1970 0.75
131 Treatment of angina pectoris with chromonar hydrochloride. Clin Pharmacol Ther 1968 0.75
132 A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. Am J Med Sci 1979 0.75